Want to see DCOY full AI Analyst Report?
DCOY Stock Chart & Stats
$2.97
-$0.06(-3.48%)
At close: 4:00 PM EST
$2.97
-$0.06(-3.48%)
Day’s Range― - ―
52-Week Range$2.63 - $70.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)64.09K
Market Cap
$1.76M
Enterprise Value-$4.66M
Total Cash (Recent Filing)$8.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding655,185
10 Day Avg. Volume19,238
30 Day Avg. Volume64,089
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-2.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.55
Enterprise Value/Ebitda0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of total debt reduces solvency pressure and avoids recurring interest obligations while the company funds clinical development. This gives management more flexibility than a highly leveraged biotech, although equity erosion means the balance-sheet advantage does not eliminate financing risk.
PIPE Funding For Clinical TrialsThe PIPE provides near-term capital specifically intended to advance the lead antiviral asset into clinical trials, supporting business continuity and execution over the coming months. Milestone-linked warrant potential could extend funding further if regulatory and clinical objectives are achieved.
Losses Improved Versus 2022Although the company remains unprofitable, the smaller loss than in 2022 indicates some improvement from the earlier peak cash-burn period. If maintained, better expense control could preserve runway and provide a stronger foundation for development spending before revenue begins.
Bears Say
Pre-Revenue BusinessWith no reported revenue, Decoy has not yet demonstrated commercial demand or an operating engine that can independently fund research and development. Its ability to create durable value therefore remains dependent on clinical progress, future financing, and eventual product commercialization.
Persistent Cash BurnNegative operating and free cash flow show that the business currently consumes capital to operate and develop its pipeline rather than generating funding internally. Continued burn can shorten financial runway and increase dependence on additional capital raises before any product revenue is established.
Shrinking Shareholders' EquityThe steep decline in equity indicates that sustained losses have consumed a substantial portion of the company’s capital base. This weakens financial resilience and raises the likelihood that future development may require equity financing, creating dilution risk for existing shareholders.
Decoy Therapeutics News
DCOY FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
Decoy Therapeutics lowest stock price was $2.63 and its highest was $70.80 in the past 12 months.
What is Decoy Therapeutics’s market cap?
Decoy Therapeutics’s market cap is $1.76M.
When is Decoy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decoy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Decoy Therapeutics overvalued?
According to Wall Street analysts Decoy Therapeutics’s price is currently Overvalued.
Does Decoy Therapeutics pay dividends?
Decoy Therapeutics does not currently pay dividends.
What is Decoy Therapeutics’s EPS estimate?
Decoy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decoy Therapeutics have?
Decoy Therapeutics has 655,185 shares outstanding.
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decoy Therapeutics?
Currently, no hedge funds are holding shares in DCOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decoy Therapeutics
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.